[Therapeutic monoclonal antibodies against multiple myeloma]

Junya Kuroda

研究成果: Contribution to journalArticle査読

抄録

Multiple myeloma (MM) remains mostly incurable despite the recent progress in the treatment strategy. One of novel fields for anti-MM therapeutic strategy is the development of immunotherapy using monoclonal antibodies (MoAbs) against myeloma-specific antigens. This article focuses on the basic and clinical aspects of several emerging and promising novel MoAbs for MM, such as elotuzumab which targets CS1 and daratumumab which targets CD38. Both antigens are highly expressed in more than 90% of MM patients, and the clinical trials have shown promising anti-MM effects, especially in combination with immunomodulatory agent lenalidomide. We also discuss the characteristics and the results of clinical trials of other MoAbs, such as tabalumab against B cell activating factor or dacetuzumab against CD40, being developed for MM.

本文言語英語
ページ(範囲)119-123
ページ数5
ジャーナルNippon rinsho. Japanese journal of clinical medicine
73
1
出版ステータス出版済み - 1 1 2015
外部発表はい

All Science Journal Classification (ASJC) codes

  • Medicine(all)

フィンガープリント 「[Therapeutic monoclonal antibodies against multiple myeloma]」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル